(Nasdaq: LFMD), a leading provider of virtual primary care services, today announced the launch of Novo Nordisk's new Wegovy (semaglutide) subscription program the first and only GLP-1 subscription offering of its kind now available through LifeMD
Obesity In a survey done in 2022, approximately 38.6 percent of Filipino adults aged 20 to 59 were overweight or obese
MedBound Hub GLP-1 Drugs: Fighting Diabetes and Weight Gain General Madhumathi.N.Lambi December 25, 2025, 1:49pm 1 GLP-1 Drugs: Fighting Diabetes and Weight In recent years, GLP-1 receptor agonists have transformed the treatment landscape for type 2 diabetes and obesity, blurring the line between metabolic disease management and weight-loss therapy
Similarly, Kitazawa et al
[2] Ozempic and Wegovy, also known as GLP-1 agonist medications, have become household names
This face and body care will reveal your radiance